|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INS |
Gene summary for INS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INS | Gene ID | 3630 |
| Gene name | insulin | |
| Gene Alias | IDDM | |
| Cytomap | 11p15.5 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | I3WAC9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3630 | INS | HTA12-15-2 | Human | Pancreas | PDAC | 4.21e-07 | 6.33e-01 | 0.2315 |
| 3630 | INS | HTA12-16-5 | Human | Pancreas | PDAC | 1.34e-09 | 5.46e-01 | 0.047 |
| 3630 | INS | HTA12-29-1 | Human | Pancreas | PDAC | 1.10e-17 | 5.45e-01 | 0.3722 |
| 3630 | INS | HTA12-9-1 | Human | Pancreas | PDAC | 1.54e-02 | 3.32e-01 | 0.1532 |
| 3630 | INS | HTA12-9-2 | Human | Pancreas | PDAC | 3.02e-06 | -8.82e-01 | 0.0835 |
| 3630 | INS | 3829-EC | Human | Pancreas | PanIN | 3.51e-44 | 7.24e-01 | 0.009 |
| 3630 | INS | 4347-EC | Human | Pancreas | PanIN | 4.13e-187 | 1.20e+00 | 0.0572 |
| 3630 | INS | 4741-EC1 | Human | Pancreas | PanIN | 1.43e-45 | 8.66e-01 | 0.0223 |
| 3630 | INS | 181429 | Human | Pancreas | PDAC | 1.38e-04 | -1.64e+00 | 0.1416 |
| 3630 | INS | DS20191261Tumor | Human | Pancreas | PDAC | 1.19e-32 | -1.64e+00 | 0.1367 |
| 3630 | INS | DS20191261TumorKeller | Human | Pancreas | PDAC | 1.12e-06 | -1.64e+00 | 0.1407 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004603414 | Breast | IDC | ATP metabolic process | 85/1434 | 277/18723 | 6.42e-30 | 1.82e-26 | 85 |
| GO:000609113 | Breast | IDC | generation of precursor metabolites and energy | 103/1434 | 490/18723 | 1.53e-21 | 1.74e-18 | 103 |
| GO:001598013 | Breast | IDC | energy derivation by oxidation of organic compounds | 73/1434 | 318/18723 | 8.70e-18 | 3.80e-15 | 73 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| GO:004440314 | Breast | IDC | biological process involved in symbiotic interaction | 52/1434 | 290/18723 | 6.55e-09 | 5.03e-07 | 52 |
| GO:000915014 | Breast | IDC | purine ribonucleotide metabolic process | 55/1434 | 368/18723 | 1.30e-06 | 5.72e-05 | 55 |
| GO:001969314 | Breast | IDC | ribose phosphate metabolic process | 58/1434 | 396/18723 | 1.31e-06 | 5.73e-05 | 58 |
| GO:000675313 | Breast | IDC | nucleoside phosphate metabolic process | 68/1434 | 497/18723 | 2.01e-06 | 8.23e-05 | 68 |
| GO:000911713 | Breast | IDC | nucleotide metabolic process | 67/1434 | 489/18723 | 2.28e-06 | 9.05e-05 | 67 |
| GO:005165114 | Breast | IDC | maintenance of location in cell | 37/1434 | 214/18723 | 2.39e-06 | 9.35e-05 | 37 |
| GO:000925914 | Breast | IDC | ribonucleotide metabolic process | 56/1434 | 385/18723 | 2.47e-06 | 9.63e-05 | 56 |
| GO:005170114 | Breast | IDC | biological process involved in interaction with host | 35/1434 | 203/18723 | 4.72e-06 | 1.63e-04 | 35 |
| GO:000616314 | Breast | IDC | purine nucleotide metabolic process | 56/1434 | 396/18723 | 5.90e-06 | 1.90e-04 | 56 |
| GO:004693913 | Breast | IDC | nucleotide phosphorylation | 22/1434 | 101/18723 | 6.31e-06 | 1.98e-04 | 22 |
| GO:004518514 | Breast | IDC | maintenance of protein location | 21/1434 | 94/18723 | 6.69e-06 | 2.05e-04 | 21 |
| GO:007097213 | Breast | IDC | protein localization to endoplasmic reticulum | 18/1434 | 74/18723 | 8.58e-06 | 2.47e-04 | 18 |
| GO:005123513 | Breast | IDC | maintenance of location | 48/1434 | 327/18723 | 9.90e-06 | 2.77e-04 | 48 |
| GO:007252114 | Breast | IDC | purine-containing compound metabolic process | 57/1434 | 416/18723 | 1.28e-05 | 3.31e-04 | 57 |
| GO:000616513 | Breast | IDC | nucleoside diphosphate phosphorylation | 21/1434 | 99/18723 | 1.57e-05 | 3.94e-04 | 21 |
| GO:003250714 | Breast | IDC | maintenance of protein location in cell | 16/1434 | 65/18723 | 2.29e-05 | 5.51e-04 | 16 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | IDC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Precancer |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Precancer |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | CRC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | FAP |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | MSI-H |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | MSS |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | AEH |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | EEC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Esophagus | ESCC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | GC | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | GC | GC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |